how to use melanotan 2: Frequently asked questions

Reduce the dose by 0.5mg on the next administration. Persistent nausea indicates you've exceeded the subject's melanocortin-4 receptor tolerance threshold in the area postrema (the brainstem region that triggers the vomiting reflex). Doses above 1.5mg produce nausea in 50–70% of subjects regardless of receptor sensitivity. Pre-dosing with 25mg ondansetron 30 minutes before MT-2 administration suppresses nausea without interfering with central arousal effects. This is common practice in tanning protocols but less necessary at libido-range doses.

Reduce dose to 0.1–0.15mg daily and extend loading phase to 21–28 days. Nausea results from MT-2 binding to melanocortin-4 receptors (MC4R) in the hypothalamus, which regulate appetite and emesis pathways. Lower doses reduce MC4R activation while still saturating MC1R on melanocytes. Administer injections in the evening before bed so nausea occurs during sleep. Anti-nausea agents (ondansetron, meclizine) are effective if needed, but most users acclimate within 7–10 days as MC4R sensitivity downregulates with repeated exposure.

Discard it. Peptides stored above 8°C for more than 4 hours undergo irreversible degradation. The solution will look identical, but potency drops by an estimated 30–60% depending on ambient temperature. You can't test potency at home, and injecting degraded peptide wastes both the compound and the protocol day. Reconstitute a fresh vial and resume dosing.

Reduce the next dose by 50% and take it with a small meal containing fat and protein 30 minutes before injection. Nausea intensity correlates directly with dose size and rate of plasma concentration increase. Splitting a 1mg dose into two 0.5mg injections 12 hours apart often eliminates nausea entirely while preserving erectile effects. Ginger supplements (1g) or ondansetron (4mg, prescription) taken 30 minutes pre-dose also reduce nausea incidence. If nausea persists beyond 90 minutes or includes vomiting, the dose exceeded your tolerance threshold. Wait 48 hours and restart at 0.25mg.

Tan fade rate depends on epidermal turnover speed, which averages 28–40 days. Restarting maintenance at 0.5mg twice weekly will restore colour within 5–7 days without requiring a full loading phase. Your melanocytes retain 'memory' of prior MT-2 exposure through persistent MC1R upregulation. If you want to maintain colour during a break from injections, introduce 10–15 minutes of UVA exposure twice weekly. This provides enough UV stimulus to sustain melanin production without MT-2's pharmacological MC1R activation.

Verify reconstitution accuracy. Improper mixing or degraded peptide from temperature excursion during shipping is the most common cause of non-response. A correctly reconstituted 10mg vial in 2mL bacteriostatic water should yield exactly 0.5mg per 0.1mL (10 units on an insulin syringe). If you injected 0.5mg and felt nothing, increase to 1mg for the next dose. Approximately 15% of users require 1.5–2mg to reach threshold receptor occupancy for spontaneous erections. If 2mg produces no effect after two attempts, the issue is either product degradation or atypical melanocortin receptor expression.

No. MT-2 doesn't accumulate, and there's no 'catch-up' mechanism. Simply resume at your standard dose the next day before your target meal. Missing doses doesn't cause rebound hunger the way stopping GLP-1 medications does. MT-2's effect is strictly acute, tied to active receptor occupancy.

Reduce the dose by 50% immediately. Nausea at doses above 500 mcg indicates you've exceeded the appetite-suppression threshold and entered the side-effect range. True MC4R-mediated satiety feels like reduced food interest, not gastric discomfort. If nausea persists at 250 mcg, MT-2 likely isn't compatible with your individual MC4R receptor density. Some individuals have heightened receptor sensitivity that produces nausea even at low doses.

Shorten maintenance intervals to every 60 hours instead of 72–96 hours, and add one additional 10-minute UV session per week. Rapid fade (noticeable within 5–7 days) suggests individual variation in melanin turnover rates. Some research subjects metabolise eumelanin 30–40% faster than population average. Increasing peptide dose does not correct this; increased UV frequency does.

Drop to 125mcg daily and extend loading phase to 14 days instead of 10. Persistent nausea (beyond Day 5–7) indicates individual sensitivity to α-MSH analogues. Forcing through at 250mcg increases dropout rates without improving outcomes. Co-administering with food reduces gastric side effects by 40–50% in sensitive research models.

Discard the vial if ambient temperature exceeded 25°C for more than 6 hours. Peptide aggregation is time- and temperature-dependent; even 8–10 hours at 22–25°C causes measurable potency loss. A vial exposed to 30°C+ overnight is completely inactive. Continuing use wastes the remaining protocol and produces no further pigmentation regardless of dosing.

Increase daily dose to 0.75mg and extend loading phase to 21 days. Some individuals with Fitzpatrick type I skin and red hair (MC1R variant genotypes) show delayed or minimal response to MT-2 because their melanocytes produce primarily pheomelanin (red-yellow pigment) rather than eumelanin (brown-black pigment). The peptide still binds MC1R, but the downstream melanin synthesis pathway doesn't shift pigment type. If no visible change occurs by day 21 at 0.75mg, further dose escalation is unlikely to help. Your melanocyte genetics may not support eumelanin production at levels that create visible tan.

This indicates melanocyte activation from cumulative melanocortin-1 receptor (MC1R) stimulation. It occurs at doses >1mg administered more than twice weekly or at any dose if exposure to UV light occurs within 48 hours of administration. Hyperpigmentation at libido-range doses (0.5–1.5mg, 2–3x/week) without UV exposure is uncommon but not impossible in subjects with high baseline melanocyte density. If pigmentation is undesirable, reduce dosing frequency to once weekly or lower the dose to 0.5mg. Existing pigmentation fades over 4–8 weeks after cessation but does not reverse completely.

Increase to 0.75mg for three separate administrations before concluding non-response. Some subjects have lower melanocortin receptor density in hypothalamic nuclei, requiring higher doses to achieve threshold activation. If 0.75mg produces no effect after three trials, escalate to 1.0mg. Non-response at 1.5mg indicates either receptor polymorphism, prior desensitisation from chronic melanocortin agonist exposure, or incorrect administration technique. Verify injection depth. Subcutaneous, not intramuscular. And confirm the reconstituted solution hasn't been stored above 8°C, which denatures the peptide.

Reduce UV exposure on darker areas and extend sessions on lighter areas by 3–5 minutes per session. Uneven pigmentation typically reflects regional differences in melanocyte density (face and forearms darken faster than torso). Adjusting UV timing per region rather than increasing peptide dose corrects this within 2–3 weeks.

Reduce your dose to 0.25mg and extend the loading phase to 10 days instead of increasing to 0.5mg. Nausea is mediated by MC4R activation in the hypothalamus, which has a lower affinity for MT-II than MC1R but still binds at doses above 0.4mg in sensitive individuals. The nausea does not indicate peptide contamination or allergic reaction. It's a predictable off-target effect. Ginger supplementation (500mg) or taking the injection in the evening (so nausea occurs during sleep) helps some users, but dose reduction is the most reliable mitigation.

Delay starting MT-II until you have consistent UV access. Injecting the peptide without UV produces MC1R activation but no melanin synthesis. You waste the loading phase and risk receptor desensitisation. Melanocytes upregulate tyrosinase in response to MT-II, but that enzyme has no substrate to act on without UV-induced DNA damage triggering melanin precursor production. If you start loading and then can't access UV for 4–5 days, the receptor saturation you built dissipates, requiring you to restart loading from day 1.

You exceeded your UV dose relative to your current melanin density. Reduce UV exposure time by 30–40% in the next session and ensure you're injecting 4–6 hours before UV, not immediately before. Erythema (redness) occurs when UVB-induced DNA damage overwhelms the skin's repair mechanisms faster than melanocytes can synthesise protective melanin. MT-II accelerates melanin production but doesn't eliminate the erythemal threshold. It shifts it upward, not removes it. If redness persists beyond 24 hours or blistering occurs, discontinue UV exposure for 48–72 hours while maintaining MT-II injections, then resume at 50% of the previous UV duration.

You're likely dosing at the wrong time relative to meals. MT-2's appetite effect is meal-window-specific, not continuous. Inject 60–90 minutes before your largest meal and assess hunger levels 30–60 minutes post-injection. If still no effect after timing adjustment, increase to 750 mcg. But monitor closely for nausea. Doses above 1mg daily produce more side effects than incremental appetite benefits.

Transition to a maintenance protocol: 0.25–0.5mg subcutaneously 2–3 times per week. This schedule maintains steady-state melanocortin receptor activation without daily injection burden or cumulative side effect buildup. Studies on bremelanotide (a related MC4R agonist) demonstrated sustained efficacy over 52 weeks at twice-weekly dosing with no tachyphylaxis. Rotate injection sites rigorously and monitor for skin hyperpigmentation. Cumulative melanocortin exposure darkens skin tone gradually over months. Most users report 1–2 shade darkening after 12 weeks at maintenance dosing.